Serving the Society Since 1986
Advanced Search
Volume 36 Issue 2
April 2021
    Citation: Xiangchuan He, Miaomiao Zhang, Chen Zhao, Peiyong Zheng, Xiaoyan Zhang, Jianqing Xu. From Monovalent to Multivalent Vaccines, the Exploration for Potential Preventive Strategies Against Hand, Foot, and Mouth Disease (HFMD) .VIROLOGICA SINICA, 2021, 36(2) : 167-175.  http://dx.doi.org/10.1007/s12250-020-00294-3
    shu

    From Monovalent to Multivalent Vaccines, the Exploration for Potential Preventive Strategies Against Hand, Foot, and Mouth Disease (HFMD)

    • 1.

      Shanghai Public Health Clinical Center and Institutes of Biomedical Science, Shanghai Medical College, Fudan University, Shanghai 201508, China

    • 2.

      Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China

    • Corresponding author: Xiaoyan Zhang, zhangxiaoyan@shphc.org.cn, ORCID: 0000-0002-3193-1401
      Jianqing Xu, xujianqing@shphc.org.cn, ORCID: 0000-0003-0896-9273
    • Received Date: 22 April 2020
      Accepted Date: 25 August 2020
      Published Date: 30 September 2020
      Available online: 01 April 2021

    • Hand, foot, and mouth disease (HFMD) recently emerged as a global public threat. The licensure of inactivated enterovirus A71 (EV-A71) vaccine was the first step in using a vaccine to control HFMD. New challenges arise from changes in the pathogen spectrum while vaccines directed against other common serotypes are in the preclinical stage. The mission of a broad-spectrum prevention strategy clearly favors multivalent vaccines. The development of multivalent vaccines was attempted via the simple combination of potent monovalent vaccines or the construction of chimeric vaccines comprised of epitopes derived from different virus serotypes. The present review summarizes recent advances in HFMD vaccine development and discusses the next steps toward a safe and effective HFMD vaccine that is capable of establishing a cross-protective antibody response.

    • 加载中

      1. Anasir MI, Poh CL (2019) Advances in antigenic peptide-based vaccine and neutralizing antibodies against viruses causing hand, foot, and mouth disease. Int J Mol Sci 20:1256
          doi: 10.3390/ijms20061256

      2. Arthur Huang KY, Chen MF, Huang YC, Shih SR, Chiu CH, Lin JJ, Wang JR, Tsao KC, Lin TY (2017) Epitope-associated and specificity-focused features of EV71-neutralizing antibody repertoires from plasmablasts of infected children. Nat Commun 8:762
          doi: 10.1038/s41467-017-00736-9

      3. Aw-Yong KL, NikNadia NMN, Tan CW, Sam IC, Chan YF (2019) Immune responses against enterovirus A71 infection: implications for vaccine success. Rev Med Virol 29:e2073

      4. Bian L, Gao F, Mao Q, Sun S, Wu X, Liu S, Yang X, Liang Z (2019) Hand, foot, and mouth disease associated with coxsackievirus A10: more serious than it seems. Expert Rev Anti Infect Ther 17:233–242
          doi: 10.1080/14787210.2019.1585242

      5. Cai Y, Ku Z, Liu Q, Leng Q, Huang Z (2014) A combination vaccine comprising of inactivated enterovirus 71 and coxsackievirus A16 elicits balanced protective immunity against both viruses. Vaccine 32:2406–2412
          doi: 10.1016/j.vaccine.2014.03.012

      6. Caine EA, Fuchs J, Das SC, Partidos CD, Osorio JE (2015) Efficacy of a trivalent hand, foot, and mouth disease vaccine against enterovirus 71 and coxsackieviruses A16 and A6 in mice. Viruses 7:5919–5932
          doi: 10.3390/v7112916

      7. Cao RY, Dong DY, Liu RJ, Han JF, Wang GC, Zhao H, Li XF, Deng YQ, Zhu SY, Wang XY, Lin F, Zhang FJ, Chen W, Qin ED, Qin CF (2013) Human IgG Subclasses against Enterovirus Type 71: neutralization versus Antibody Dependent Enhancement of Infection. PLoS ONE 8:e64024
          doi: 10.1371/journal.pone.0064024

      8. Chen J, Zhang C, Zhou Y, Zhang X, Shen C, Ye X, Jiang W, Huang Z, Cong Y (2018) A 3.0-angstrom resolution cryo-electron microscopy structure and antigenic sites of coxsackievirus A6-like particles. J Virol 92:e01257-17

      9. Chen C, Xia Y, Zhu S, Xu F, Sun Y, Lu H, Gao M, Yang Z, Mao Z, Ge Q (2020) Muscle destruction caused by coxsackievirus A10 in gerbils: construction of a novel animal model for antiviral evaluation. Virus Res 286:198067
          doi: 10.1016/j.virusres.2020.198067

      10. Chung CY, Chen CY, Lin SY, Chung YC, Chiu HY, Chi WK, Lin YL, Chiang BL, Chen WJ, Hu YC (2010) Enterovirus 71 virus-like particle vaccine: improved production conditions for enhanced yield. Vaccine 28:6951–6957
          doi: 10.1016/j.vaccine.2010.08.052

      11. Dai W, Xiong P, Zhang X, Liu Z, Chen J, Zhou Y, Ye X, Zhang C (2019) Recombinant virus-like particle presenting a newly identified coxsackievirus A10 neutralization epitope induces protective immunity in mice. Antiviral Res 164:139–146
          doi: 10.1016/j.antiviral.2019.02.016

      12. Fan S, Liao Y, Jiang G, Jiang L, Wang L, Xu X, Feng M, Yang E, Zhang Y, Cui W, Li Q (2020) Study of integrated protective immunity induced in rhesus macaques by the intradermal administration of a bivalent EV71-CA16 inactivated vaccine. Vaccine 38:2034–2044
          doi: 10.1016/j.vaccine.2019.12.057

      13. Fang CY, Liu CC (2018) Recent development of enterovirus A vaccine candidates for the prevention of hand, foot, and mouth disease. Expert Rev Vaccines 17:819–831
          doi: 10.1080/14760584.2018.1510326

      14. Foo DGW, Alonso S, Phoon MC, Ramachandran N, Chow VTK, Poh CL (2007) Identification of neutralizing linear epitopes from the VP1 capsid protein of Enterovirus 71 using synthetic peptides. Virus Res 125:61–68
          doi: 10.1016/j.virusres.2006.12.005

      15. Fujii K, Nagata N, Sato Y, Ong KC, Wong KT, Yamayoshi S, Shimanuki M, Shitara H, Taya C, Koike S (2013) Transgenic mouse model for the study of enterovirus 71 neuropathogenesis. PNAS 110:14753–14758
          doi: 10.1073/pnas.1217563110

      16. Guan X, Che Y, Wei S, Li S, Zhao Z, Tong Y, Wang L, Gong W, Zhang Y, Zhao Y (2019) Effectiveness and safety of an inactivated enterovirus 71 vaccine in children aged 6–71 months in a phase IV study. Clin Infect Dis. https://doi.org/10.1093/cid/ciz1114

      17. Huang LM, Chiu CH, Chiu NC, Lin CY, Li MT, Kuo TY, Weng YJ, Hsieh EF, Tai IC (2019) Immunogenicity, safety, cross-reaction, and immune persistence of an inactivated enterovirus A71 vaccine in children aged from two months to 11 years in Taiwan. Vaccine 37:1827–1835
          doi: 10.1016/j.vaccine.2019.02.023

      18. Huo C, Yang J, Lei L, Qiao L, Xin J, Pan Z (2017) Hepatitis B virus core particles containing multiple epitopes confer protection against enterovirus 71 and coxsackievirus A16 infection in mice. Vaccine 35:7322–7330
          doi: 10.1016/j.vaccine.2017.10.101

      19. Jia Q, Ng Q, Chin W, Meng T, Chow VTK, Wang C-I, Kwang J, He F (2017) Effective in vivo therapeutic IgG antibody against VP3 of enterovirus 71 with receptor-competing activity. Sci Rep 7:46402
          doi: 10.1038/srep46402

      20. Jiang L, Fan R, Sun S, Fan P, Su W, Zhou Y, Gao F, Xu F, Kong W, Jiang C (2015) A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice. Vaccine 33:6596–6603
          doi: 10.1016/j.vaccine.2015.10.104

      21. Kiener TK, Jia Q, Meng T, Chow VTK, Kwang J (2014) A novel universal neutralizing monoclonal antibody against enterovirus 71 that targets the highly conserved "knob" region of VP3 protein. PLoS Negl Trop Dis 8:e2895
          doi: 10.1371/journal.pntd.0002895

      22. Ku Z, Liu Q, Ye X, Cai Y, Wang X, Shi J, Li D, Jin X, An W, Huang Z (2014) A virus-like particle based bivalent vaccine confers dual protection against enterovirus 71 and coxsackievirus A16 infections in mice. Vaccine 32:4296–4303
          doi: 10.1016/j.vaccine.2014.06.025

      23. Lee H, Cifuente JO, Ashley RE, Conway JF, Makhov AM, Tano Y, Shimizu H, Nishimura Y, Hafenstein S (2013) A strain-specific epitope of enterovirus 71 identified by cryo-electron microscopy of the complex with fab from neutralizing antibody. J Virol 87:11363–11370
          doi: 10.1128/JVI.01926-13

      24. Li HY, Han JF, Qin CF, Chen R (2013) Virus-like particles for enterovirus 71 produced from Saccharomyces cerevisiae potently elicits protective immune responses in mice. Vaccine 31:3281–3287
          doi: 10.1016/j.vaccine.2013.05.019

      25. Li J, Chang J, Liu X, Yang J, Guo H, Wei W, Zhang W, Yu XF (2014) Protection from lethal challenge in a neonatal mouse model by circulating recombinant form coxsackievirus A16 vaccine candidates. J Gen Virol 95:1083
          doi: 10.1099/vir.0.063560-0

      26. Li R, Liu L, Mo Z, Wang X, Xia J, Liang Z, Zhang Y, Li Y, Mao Q, Wang J, Jiang L, Dong C, Che Y, Huang T, Jiang Z, Xie Z, Wang L, Liao Y, Liang Y, Nong Y, Liu J, Zhao H, Na R, Guo L, Pu J, Yang E, Sun L, Cui P, Shi H, Wang J, Li Q (2014) An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med 370:829–837
          doi: 10.1056/NEJMoa1303224

      27. Li JX, Song YF, Wang L, Zhang XF, Hu YS, Hu YM, Xia JL, Li J, Zhu FC (2016) Two-year efficacy and immunogenicity of Sinovac Enterovirus 71 vaccine against hand, foot and mouth disease in children. Expert Rev Vaccines 15:129–137
          doi: 10.1586/14760584.2016.1096782

      28. Lim HX, Poh CL (2019) Insights into innate and adaptive immune responses in vaccine development against EV-A71. Ther Adv Vaccines Immunother 7:2515135519888998

      29. Lim H, In HJ, Lee JA, Sik Yoo J, Lee SW, Chung GT, Choi YK, Chung JK, Cho SJ, Lee JW (2018) The immunogenicity and protection effect of an inactivated coxsackievirus A6, A10, and A16 vaccine against hand, foot, and mouth disease. Vaccine 36:3445–3452
          doi: 10.1016/j.vaccine.2018.05.005

      30. Lin JY, Kung YA, Shih SR (2019) Antivirals and vaccines for Enterovirus A71. J Biomed Sci 26:65
          doi: 10.1186/s12929-019-0560-7

      31. Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, Chang JY, Guo MS, Chow YH, Yang WS, Chang KHW, Sia C, Chong P (2011) Identification and characterization of a cross-neutralization epitope of Enterovirus 71. Vaccine 29:4362–4372
          doi: 10.1016/j.vaccine.2011.04.010

      32. Liu L, Zhao H, Zhang Y, Wang J, Che Y, Dong C, Zhang X, Na R, Shi H, Jiang L (2011) Neonatal rhesus monkey is a potential animal model for studying pathogenesis of EV71 infection. Virology 412:91–100
          doi: 10.1016/j.virol.2010.12.058

      33. Mao Q, Wang Y, Bian L, Xu M, Liang Z (2016) EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases. Emerg Microbes Infect 5:1–7

      34. Plevka P, Lim P-Y, Perera R, Cardosa J, Suksatu A, Kuhn RJ, Rossmann MG (2014) Neutralizing antibodies can initiate genome release from human enterovirus 71. PNAS 111:2134–2139
          doi: 10.1073/pnas.1320624111

      35. Premanand B, Kiener TK, Meng T, Tan YR, Jia Q, Chow VT, Kwang J (2012) Induction of protective immune responses against EV71 in mice by baculovirus encoding a novel expression cassette for capsid protein VP1. Antiviral Res 95:311–315
          doi: 10.1016/j.antiviral.2012.05.017

      36. Qi An W, Guo SuZ, Wen Pan R, Ping Yang B, Chao Zhang Y, Shi L, Li Q (2014) The immunogenicity and protection effect of the BPL-inactivated CA16 vaccine in different animal systems. Hum Vaccin Immunother 10:628–639
          doi: 10.4161/hv.27295

      37. Somasundaram B, Chang C, Fan YY, Lim PY, Cardosa J, Lua L (2016) Characterizing Enterovirus 71 and Coxsackievirus A16 virus-like particles production in insect cells. Methods 95:38–45
          doi: 10.1016/j.ymeth.2015.09.023

      38. Song Y, Zhang Y, Ji T, Gu X, Yang Q, Zhu S, Xu W, Xu Y, Shi Y, Huang X, Li Q, Deng H, Wang X, Yan D, Yu W, Wang S, Yu D, Xu W (2017) Persistent circulation of Coxsackievirus A6 of genotype D3 in mainland of China between 2008 and 2015. Sci Rep 7:5491
          doi: 10.1038/s41598-017-05618-0

      39. Sun YS, Li YJ, Xia Y, Xu F, Wang WW, Yang ZN, Lu HJ, Chen ZP, Miao ZP, Liang WF, Xu ZY, Dong HJ, Qiu DH, Zhu ZY, van der Veen S, Qian J, Zhou B, Yao PP, Zhu HP (2016) Coxsackievirus A16 induced neurological disorders in young gerbils which could serve as a new animal model for vaccine evaluation. Sci Rep 6:1–11
          doi: 10.1038/s41598-016-0001-8

      40. Tsou YL, Lin YW, Shao HY, Yu SL, Wu SR, Lin HY, Liu CC, Huang C, Chong P, Chow YH (2015) Recombinant adeno-vaccine expressing enterovirus 71-like particles against hand, foot, and mouth disease. PLoS NTD 9:e0003692

      41. Wang YF, Yu CK (2014) Animal models of enterovirus 71 infection: applications and limitations. J Biomed Sci 21:31
          doi: 10.1186/1423-0127-21-31

      42. Wang KT, Lin SJ, Wang HC, Chen PC, Lin JJ, Chiang JR, Chang CL, Shih DY, Lo CF, Wang DY (2016) Establishment of an animal challenge model as a potency assay for an inactivated Enterovirus Type 71 vaccine. Biologicals 44:183–190
          doi: 10.1016/j.biologicals.2016.01.003

      43. Wang J, Zhang Y, Zhang X, Hu Y, Dong C, Liu L, Yang E, Che Y, Pu J, Wang X (2017) Pathologic and immunologic characteristics of coxsackievirus A16 infection in rhesus macaques. Virology 500:198–208
          doi: 10.1016/j.virol.2016.10.031

      44. Wang J, Teng Z, Cui X, Li C, Pan H, Zheng Y, Mao S, Yang Y, Wu L, Guo X, Zhang X, Zhu Y (2018) Epidemiological and serological surveillance of hand-foot-and-mouth disease in Shanghai, China, 2012–2016. Emerg Microbes Infect 7:8

      45. Wang X, Ku Z, Zhang X, Ye X, Chen J, Liu Q, Zhang W, Zhang C, Fu Z, Jin X, Cong Y, Huang Z (2018) Structure, immunogenicity, and protective mechanism of an Engineered Enterovirus 71-like particle vaccine mimicking 80S empty capsid. J Virol 92:e01330–17

      46. Xu L, He D, Yang L, Li Z, Ye X, Yu H, Zhao H, Li S, Yuan L, Qian H, Que Y, Shih JW, Zhu H, Li Y, Cheng T, Xia N (2015) A broadly cross-protective vaccine presenting the neighboring epitopes within the VP1 GH loop and VP2 EF loop of enterovirus 71. Sci Rep 5:12973
          doi: 10.1038/srep12973

      47. Yan Q, Wu L, Chen L, Qin Y, Pan Z, Chen M (2016) Vesicular stomatitis virus-based vaccines expressing EV71 virus-like particles elicit strong immune responses and protect newborn mice from lethal challenges. Vaccine 34:4196–4204
          doi: 10.1016/j.vaccine.2016.06.058

      48. Yang B, Chuang H, Yang KD (2009) Sialylated glycans as receptor and inhibitor of enterovirus 71 infection to DLD-1 intestinal cells. Virol J 6:141
          doi: 10.1186/1743-422X-6-141

      49. Yang L, Liu Y, Li S, Zhao H, Lin Q, Yu H, Huang X, Zheng Q, Cheng T, Xia N (2016) A novel inactivated enterovirus 71 vaccine can elicit cross-protective immunity against coxsackievirus A16 in mice. Vaccine 34:5938–5945
          doi: 10.1016/j.vaccine.2016.10.018

      50. Yang Z, Gao F, Wang X, Shi L, Zhou Z, Jiang Y, Ma X, Zhang C, Zhou C, Zeng X, Liu G, Fan J, Mao Q, Shi L (2019) Development and characterization of an enterovirus 71 (EV71) virus-like particles (VLPs) vaccine produced in Pichia pastoris. Hum Vaccin Immunother. https://doi.org/10.1080/21645515.2019.1649554:1-9

      51. Yao PP, Miao ZP, Xu F, Lu HJ, Sun YS, Xia Y, Chen C, Yang ZN, Xia SC, Jm Jiang (2019) An adult gerbil model for evaluating potential coxsackievirus A16 vaccine candidates. Vaccine 37:5341–5349
          doi: 10.1016/j.vaccine.2019.07.046

      52. Yee PTI, Poh CL (2018) T Cell immunity to enterovirus 71 infection in humans and implications for vaccine development. Int J Med Sci 15:1143
          doi: 10.7150/ijms.26450

      53. Yi EJ, Shin YJ, Kim JH, Kim TG, Chang SY (2017) Enterovirus 71 infection and vaccines. Clin Exp Vaccine Res 6:4–14
          doi: 10.7774/cevr.2017.6.1.4

      54. Yu CK, Chen CC, Chen CL, Wang JR, Liu CC, Yan JJ, Su IJ (2000) Neutralizing antibody provided protection against enterovirus type 71 lethal challenge in neonatal mice. J Biomed Sci 7:523–528
          doi: 10.1007/BF02253368

      55. Zhang C, Yang Y, Chi Y, Yin J, Yan L, Ku Z, Liu Q, Huang Z, Zhou D (2015) Hexon-modified recombinant E1-deleted adenoviral vectors as bivalent vaccine carriers for Coxsackievirus A16 and Enterovirus 71. Vaccine 33:5087–5094
          doi: 10.1016/j.vaccine.2015.08.016

      56. Zhang C, Liu Q, Ku Z, Hu Y, Ye X, Zhang Y, Huang Z (2016) Coxsackievirus A16-like particles produced in Pichia pastoris elicit high-titer neutralizing antibodies and confer protection against lethal viral challenge in mice. Antiviral Res 129:47–51
          doi: 10.1016/j.antiviral.2016.02.011

      57. Zhang Z, Dong Z, Li J, Carr MJ, Zhuang D, Wang J, Zhang Y, Ding S, Tong Y, Li D (2017a) Protective efficacies of formaldehyde-inactivated whole-virus vaccine and antivirals in a murine model of coxsackievirus A10 infection. J Virol 91:e00333-17

      58. Zhang Z, Dong Z, Wei Q, Carr MJ, Li J, Ding S, Tong Y, Li D, Shi W (2017b) A neonatal murine model of coxsackievirus A6 infection for evaluation of antiviral and vaccine efficacy. J Virol 91:e02450–16

      59. Zhang W, Dai W, Zhang C, Zhou Y, Xiong P, Wang S, Ye X, Liu Q, Zhou D, Huang Z (2018) A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity. Emerg Microbes Infect 7:94

      60. Zhang Z, Dong Z, Wang Q, Carr MJ, Li J, Liu T, Li D, Shi W (2018) Characterization of an inactivated whole-virus bivalent vaccine that induces balanced protective immunity against coxsackievirus A6 and A10 in mice. Vaccine 36:7095–7104
          doi: 10.1016/j.vaccine.2018.09.069

      61. Zhao H, Li HY, Han JF, Deng YQ, Li YX, Zhu SY, He YL, Qin ED, Chen R, Qin CF (2013) Virus-like particles produced in Saccharomyces cerevisiae elicit protective immunity against Coxsackievirus A16 in mice. Appl Microbiol Biotechnol 97:10445–10452
          doi: 10.1007/s00253-013-5257-3

      62. Zhao H, Li HY, Han JF, Deng YQ, Zhu SY, Li XF, Yang HQ, Li YX, Zhang Y, Qin ED, Chen R, Qin CF (2015) Novel recombinant chimeric virus-like particle is immunogenic and protective against both enterovirus 71 and coxsackievirus A16 in mice. Sci Rep 5:7878
          doi: 10.1038/srep07878

      63. Zhou Y, Shen C, Zhang C, Zhang W, Wang L, Lan K, Liu Q, Huang Z (2016) Yeast-produced recombinant virus-like particles of coxsackievirus A6 elicited protective antibodies in mice. Antiviral Res 132:165–169
          doi: 10.1016/j.antiviral.2016.06.004

      64. Zhou Y, Zhang C, Liu Q, Gong S, Geng L, Huang Z (2018) A virus-like particle vaccine protects mice against coxsackievirus A10 lethal infection. Antiviral Res 152:124–130
          doi: 10.1016/j.antiviral.2018.02.016

    • 加载中

    Figures(1) / Tables(3)

    PDF

    Article Metrics

    Article views(5506) PDF downloads(42) Cited by()

    Related
    Proportional views

      From Monovalent to Multivalent Vaccines, the Exploration for Potential Preventive Strategies Against Hand, Foot, and Mouth Disease (HFMD)

        Corresponding author: Xiaoyan Zhang, zhangxiaoyan@shphc.org.cn
        Corresponding author: Jianqing Xu, xujianqing@shphc.org.cn
      • 1. Shanghai Public Health Clinical Center and Institutes of Biomedical Science, Shanghai Medical College, Fudan University, Shanghai 201508, China
      • 2. Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
      • Received Date: 22 April 2020
      • Accepted Date: 25 August 2020
      • Published Date: 30 September 2020

      Abstract: 

      Hand, foot, and mouth disease (HFMD) recently emerged as a global public threat. The licensure of inactivated enterovirus A71 (EV-A71) vaccine was the first step in using a vaccine to control HFMD. New challenges arise from changes in the pathogen spectrum while vaccines directed against other common serotypes are in the preclinical stage. The mission of a broad-spectrum prevention strategy clearly favors multivalent vaccines. The development of multivalent vaccines was attempted via the simple combination of potent monovalent vaccines or the construction of chimeric vaccines comprised of epitopes derived from different virus serotypes. The present review summarizes recent advances in HFMD vaccine development and discusses the next steps toward a safe and effective HFMD vaccine that is capable of establishing a cross-protective antibody response.

        HTML

      Introduction